Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Transplants due to hepatitis C have dropped dramatically, especially among people with liver cancer.
Three fatty liver disease candidates miss the mark for effectiveness or safety.
The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.
People treated with the antivirals Viread, Vemlidy or Baraclude are less likely to develop hepatocellular carcinoma.
A new classification system may more accurately reflect liver-related death trends in the United States.
People with liver cirrhosis often have substantial financial burden that interferes with their care.
In the era of highly effective treatments for both viruses, HIV doesn’t speed the advancement of cirrhosis.
South Korean researchers found no difference in the rates of liver cancer, liver transplant or death based on the treatment used.
Cure rates are high, but some young people already have advanced liver damage by the time they’re treated.
Fecal microbiota transplantation can help reverse brain impairment in people with liver failure.
The VA has cured HCV in nearly 100,000 veterans, which will dramatically reduce the development of advanced liver disease and liver cancer.
People with HIV who have higher viral load and worse immune function appear to be at higher risk for hepatocellular carcinoma.
Researchers compared liver-related death rates among Mexicans, Puerto Ricans and Cubans.
Better antiretrovirals have likely mitigated HIV’s effects on the risk of end-stage liver disease and liver cancer in those with hep C.
A new study examines the clinical and economic impact of new direct-acting antivirals.
Scientists aren’t sure, but they know that the risk that a previous case of liver cancer will return remains high for those cured of hep C.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.